medmix publishes a midyear report as well as an annual report.
Ad hoc announcement pursuant to Art. 53 LR
medmix appoints René Willi as new Chief Executive Officer
medmix announces the appointment of René Willi as its new CEO, effective June 1, 2024.
Current CEO Girts Cimermans will be stepping down as of today.
Legal prohibition impacting Kettenbach/Xinial customers further clarified
Kettenbach/Xinial legally prevented from manufacture or offer for sale in Germany
Kettenbach/Xinial legally compelled to recall and destroy infringing system
medmix Switzerland Ltd. continues to enforce its rights
Ad hoc announcement pursuant to Art. 53 LR
Full-year 2023 revenue growth and profitability within communicated range
Improving trends expected throughout full-year 2024
medmix Switzerland Ltd. continues to enforce its rights
medmix Drug Delivery (Haselmeier) launches its passive needle safety device SicuroJect™ at Pharmapack Europe in Paris, further expanding its product portfolio.
medmix wins 2024 BIG Innovation Award for MIXPAC™ greenLine™ 400 mL 1:1 two-component cartridge set made from up to 100% recycled plastic.
Ad hoc announcement pursuant to Art. 53 LR
medmix (SIX: MEDX) today announced its intention to enter into a strategic investment, representing a 25% stake, in AARDEX to reinforce medmix' drug delivery business under the HaselmeierTM brand. AARDEX is a global Software as a Service (SaaS) provider of digital solutions for measuring and managing medication adherence in clinical trials.
medmix is excited to introduce ZerofloX, an innovative new flock-free micro applicator that provides a superior user experience for best esthetics.
medmix announces the sale of medmix Poland sp. z.o.o and the removal of this entity from sanctions list.
Ad hoc announcement pursuant to Art. 53 LR
Solid underlying business momentum in H1 2023 restrained by transitory factors
Strong performance expected in H2 2023 with mid-term outlook confirmed
New FY 2023 profit margin guidance reflects timing factors within H2 2023